China climbed biotech’s worry list, while Big Pharma kept shopping


In the months lead­ing up to the Trea­sury De­part­ment’s re­lease of draft rules that would lim­it US in­vest­ment in Chi­nese bio­phar­ma, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Leave a Reply

Your email address will not be published. Required fields are marked *